Skip to main content

Table 5 Effect of Doxorubicin (DOX) and different treatments of AHE on cardiac enzymatic antioxidant levels and GSH profile

From: Acacia hydaspica R. Parker prevents doxorubicin-induced cardiac injury by attenuation of oxidative stress and structural Cardiomyocyte alterations in rats

Group GSH (μM/g tissue) GR (nM/min/mg protein) GST (nM/min/mg protein) γ-GT (nM/min/mg Protein) GPx (nM/min/mg Protein)
Control 20.55 ± 0.280b 154.9 ± 0.96b 148.6 ± 0.665b 303.5 ± 0.811b 122.4 ± 0.639b
DOX 12.36 ± 0.490a 108.7 ± 1.095a 108.9 ± 1.105a 98.54 ± 1.106a 63.20 ± 1.027a
AHE alone 20.66 ± 0.237b 155.6 ± 0.439b 148.4 ± 0.815b 306.9 ± 0.401b 122.9 ± 0.285b
DOX + AHE (200) 14.37 ± 0.38a,b*,d 122.9 ± 1.14a,b,d 122.8 ± 0.984a,b,d 188.8 ± 0.095a,b,d 85.37 ± 0.540a,b,d
DOX + AHE (400) 18.59 ± 0.44a*,b, c 141.2 ± 1.00a,b,c 140.6 ± 0.723a,b,c 291.6 ± 0.69a,b,c 114.1 ± 0.845a,b,c
DOX + Sily 18.77 ± 0.360b 140.3 ± 1.55a,b 139.2 ± 0.4623a,b 289.0 ± 0.68a,b 115.9 ± 1.290a**,b
  1. Values expressed as mean ± SEM
  2. aSignificance at p < 0.0001 Vs. control group
  3. bSignificance at p < 0.0001 Vs. Doxorubicin (DOX) group
  4. cSignificance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group
  5. dSignificance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group
  6. *, **Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin